NCT04443036

Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma

Albumin-bound Paclitaxel Combined With Toripalimab as First-line/Second-line Treatment of Local Advanced or Metastatic Gastric or Gastroesophageal Junction Carcinoma: A Prospective, Open-label, Single-arm Phase II Clinical Study

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 44 (estimated)
• Sponsor: China Medical University, China · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study is to evaluate the efficacy and safety of Albumin-bound paclitaxel combined with Toripalimab as first-line/second-line treatment of local advanced or metastatic gastric or gastroesophageal junction carcinoma.

Conditions

• Gastric Carcinoma

Interventions

Type	Name	Description
DRUG	Albumin-Bound Paclitaxel	* 125mg/m2 IV d1、8，Q3W * until disease progression, lost follow-up visit, death , unacceptable toxicity
DRUG	Toripalimab	* 240 mg，IV d1，Q3W * until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration is 24 months

Timeline

• Start date: 2020-06-11
• Primary completion: 2022-12-30
• Completion: 2023-12-30
• First posted: 2020-06-23
• Last updated: 2020-06-23

Locations

1 site across 1 country: China